General Information of Drug (ID: DMSOURV)

Drug Name
Formoterol
Synonyms
Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
Indication
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [1]
Asthma CA23 Approved [2]
Intrinsic asthma N.A. Approved [1]
Pulmonary emphysema CA21.Z Approved [1]
Therapeutic Class
Sympathomimetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 344.4
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 0.000081 micromolh/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.167-0.5 h [3]
Bioavailability
The bioavailability of drug is 43% [3]
Clearance
The renal clearance of drug is 157 mL/min [4]
Elimination
Following oral administration in 2 healthy subjects, approximately 59-62% and 32-34% of an administered dose was eliminated in the urine and feces, respectively [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 10 hours [6]
Metabolism
The drug is metabolized via the direct glucuronidation of the parent drug and via O-demethylation of the parent drug followed by glucuronidation [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Eosinophilic disorders Not Available IL5 OTAFPSCO [7]
Eosinophilic disorders Not Available CXCL10 INP10 SCYB10 OTTLQ6S0 [7]
Surgical and medical procedures Not Available ADRB2 OTSDOX4Q [7]
Chemical Identifiers
Formula
C19H24N2O4
IUPAC Name
N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide
Canonical SMILES
CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
InChI
InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)
InChIKey
BPZSYCZIITTYBL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3410
ChEBI ID
CHEBI:63082
CAS Number
73573-87-2
DrugBank ID
DB00983
TTD ID
D04KJO
VARIDT ID
DR01355
INTEDE ID
DR0744
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME
DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9)
Main DME
DE5IED8 CP2C9_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME
DEGTFWK CP2CJ_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Drug Response [7]
C-X-C motif chemokine 10 (CXCL10) OTTLQ6S0 CXL10_HUMAN Drug Response [7]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Drug Response [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic asthma
ICD Disease Classification CA23.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 4.88E-01 -0.05 -0.12
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 7.10E-01 0.06 0.09
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 1.48E-01 6.33E-02 3.20E-01
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 1.74E-02 1.21E-01 4.40E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 4.79E-03 1.32E-01 7.85E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.82E-01 -1.71E-02 -9.86E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.01E-02 6.73E-02 3.36E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 2.91E-04 1.41E-01 6.14E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 7.33E-02 5.59E-02 2.99E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 5.65E-03 -7.28E-02 -1.24E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Formoterol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Budesonide DMJIBAW Minor Increased risk of hypokalemia by the combination of Formoterol and Budesonide. Asthma [CA23] [12]
Coadministration of a Drug Treating the Disease Different from Formoterol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Moderate Additive hypertensive effects by the combination of Formoterol and Methylene blue. Acquired methaemoglobinaemia [3A93] [13]
Ivosidenib DM8S6T7 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Ivosidenib. Acute myeloid leukaemia [2A60] [14]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Formoterol and Midostaurin. Acute myeloid leukaemia [2A60] [14]
Idarubicin DMM0XGL Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Idarubicin. Acute myeloid leukaemia [2A60] [14]
Arn-509 DMT81LZ Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Arn-509. Acute myeloid leukaemia [2A60] [14]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Formoterol and Gilteritinib. Acute myeloid leukaemia [2A60] [14]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Formoterol and Oliceridine. Acute pain [MG31] [14]
Ivabradine DM0L594 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Ivabradine. Angina pectoris [BA40] [14]
Bepridil DM0RKS4 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Bepridil. Angina pectoris [BA40] [14]
Bedaquiline DM3906J Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [14]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Cilostazol. Arterial occlusive disease [BD40] [14]
Posaconazole DMUL5EW Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Posaconazole. Aspergillosis [1F20] [14]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [14]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Formoterol and Droxidopa. Autonomic nervous system disorder [8D87] [15]
Ofloxacin DM0VQN3 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Ofloxacin. Bacterial infection [1A00-1C4Z] [14]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Formoterol and Clarithromycin. Bacterial infection [1A00-1C4Z] [14]
Gemifloxacin DMHT34O Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Gemifloxacin. Bacterial infection [1A00-1C4Z] [14]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Norfloxacin. Bacterial infection [1A00-1C4Z] [14]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Levofloxacin. Bacterial infection [1A00-1C4Z] [14]
Retigabine DMGNYIH Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Retigabine. Behcet disease [4A62] [14]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Eribulin. Breast cancer [2C60-2C6Y] [14]
Lapatinib DM3BH1Y Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Lapatinib. Breast cancer [2C60-2C6Y] [14]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Formoterol and Bosutinib. Breast cancer [2C60-2C6Y] [14]
Corticotropin DMP9TWZ Minor Increased risk of hypokalemia by the combination of Formoterol and Corticotropin. Chronic kidney disease [GB61] [12]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Formoterol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [14]
Levomilnacipran DMV26S8 Moderate Additive hypertensive effects by the combination of Formoterol and Levomilnacipran. Chronic pain [MG30] [16]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Halothane. Corneal disease [9A76-9A78] [14]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Sevoflurane. Corneal disease [9A76-9A78] [14]
Probucol DMVZQ2M Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Probucol. Coronary atherosclerosis [BA80] [14]
Pasireotide DMHM7JS Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Pasireotide. Cushing syndrome [5A70] [14]
Osilodrostat DMIJC9X Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Osilodrostat. Cushing syndrome [5A70] [14]
Sertraline DM0FB1J Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Sertraline. Depression [6A70-6A7Z] [14]
Selegiline DM6034S Moderate Additive hypertensive effects by the combination of Formoterol and Selegiline. Depression [6A70-6A7Z] [13]
Isocarboxazid DMAF1NB Moderate Additive hypertensive effects by the combination of Formoterol and Isocarboxazid. Depression [6A70-6A7Z] [13]
Milnacipran DMBFE74 Moderate Increased risk of rapid heart rate by the combination of Formoterol and Milnacipran. Depression [6A70-6A7Z] [16]
Escitalopram DMFK9HG Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Escitalopram. Depression [6A70-6A7Z] [14]
Desvenlafaxine DMHD4PE Moderate Increased risk of rapid heart rate by the combination of Formoterol and Desvenlafaxine. Depression [6A70-6A7Z] [16]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Formoterol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [14]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Formoterol and Deutetrabenazine. Dystonic disorder [8A02] [14]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Formoterol and Ingrezza. Dystonic disorder [8A02] [14]
Solifenacin DMG592Q Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Solifenacin. Functional bladder disorder [GC50] [14]
Ketoconazole DMPZI3Q Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Ketoconazole. Fungal infection [1F29-1F2F] [14]
Sunitinib DMCBJSR Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [14]
Procarbazine DMIK367 Moderate Additive hypertensive effects by the combination of Formoterol and Procarbazine. Hodgkin lymphoma [2B30] [13]
Saquinavir DMG814N Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [14]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [14]
Crizotinib DM4F29C Moderate Increased risk of prolong QT interval by the combination of Formoterol and Crizotinib. Lung cancer [2C25] [14]
Ceritinib DMB920Z Moderate Increased risk of prolong QT interval by the combination of Formoterol and Ceritinib. Lung cancer [2C25] [14]
Osimertinib DMRJLAT Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Osimertinib. Lung cancer [2C25] [14]
Selpercatinib DMZR15V Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Selpercatinib. Lung cancer [2C25] [14]
Lumefantrine DM29GAD Moderate Increased risk of prolong QT interval by the combination of Formoterol and Lumefantrine. Malaria [1F40-1F45] [17]
Halofantrine DMOMK1V Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Halofantrine. Malaria [1F40-1F45] [14]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Formoterol and Hydroxychloroquine. Malaria [1F40-1F45] [14]
Primaquine DMWQ16I Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Primaquine. Malaria [1F40-1F45] [14]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [14]
Arsenic trioxide DM61TA4 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [14]
Vemurafenib DM62UG5 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Vemurafenib. Melanoma [2C30] [14]
LGX818 DMNQXV8 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and LGX818. Melanoma [2C30] [14]
Panobinostat DM58WKG Moderate Increased risk of prolong QT interval by the combination of Formoterol and Panobinostat. Multiple myeloma [2A83] [14]
Siponimod DM2R86O Moderate Increased risk of prolong QT interval by the combination of Formoterol and Siponimod. Multiple sclerosis [8A40] [14]
Fingolimod DM5JVAN Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Fingolimod. Multiple sclerosis [8A40] [14]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Formoterol and Ozanimod. Multiple sclerosis [8A40] [18]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Romidepsin. Mycosis fungoides [2B01] [14]
Dasatinib DMJV2EK Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Dasatinib. Myeloproliferative neoplasm [2A20] [14]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Formoterol and Promethazine. Nausea/vomiting [MD90] [14]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Formoterol and Entrectinib. Non-small cell lung cancer [2C25] [14]
Sibutramine DMFJTDI Moderate Increased risk of rapid heart rate by the combination of Formoterol and Sibutramine. Obesity [5B80-5B81] [19]
Levomethadyl Acetate DM06HG5 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Levomethadyl Acetate. Opioid use disorder [6C43] [17]
Lofexidine DM1WXA6 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Lofexidine. Opioid use disorder [6C43] [14]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Rucaparib. Ovarian cancer [2C73] [14]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Triclabendazole. Parasitic worm infestation [1F90] [14]
Safinamide DM0YWJC Moderate Additive hypertensive effects by the combination of Formoterol and Safinamide. Parkinsonism [8A00] [13]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Formoterol and Rasagiline. Parkinsonism [8A00] [13]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Pimavanserin. Parkinsonism [8A00] [14]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Formoterol and Macimorelin. Pituitary gland disorder [5A60-5A61] [20]
Lefamulin DME6G97 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Lefamulin. Pneumonia [CA40] [14]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Degarelix. Prostate cancer [2C82] [14]
ABIRATERONE DM8V75C Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and ABIRATERONE. Prostate cancer [2C82] [14]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Formoterol and Enzalutamide. Prostate cancer [2C82] [14]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Formoterol and Relugolix. Prostate cancer [2C82] [14]
Bicalutamide DMZMSPF Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Bicalutamide. Prostate cancer [2C82] [14]
Levomepromazine DMIKFEL Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Levomepromazine. Psychotic disorder [6A20-6A25] [14]
Gatifloxacin DMSL679 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Gatifloxacin. Respiratory infection [CA07-CA4Z] [14]
Ciclesonide DM2NA4K Minor Increased risk of hypokalemia by the combination of Formoterol and Ciclesonide. Respiratory system disease [CB40-CB7Z] [12]
Dexamethasone DMMWZET Minor Increased risk of hypokalemia by the combination of Formoterol and Dexamethasone. Rheumatoid arthritis [FA20] [12]
Quetiapine DM1N62C Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Quetiapine. Schizophrenia [6A20] [14]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Formoterol and Aripiprazole. Schizophrenia [6A20] [21]
Iloperidone DM6AUFY Moderate Increased risk of prolong QT interval by the combination of Formoterol and Iloperidone. Schizophrenia [6A20] [14]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Paliperidone. Schizophrenia [6A20] [14]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Amisulpride. Schizophrenia [6A20] [14]
Asenapine DMSQZE2 Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Asenapine. Schizophrenia [6A20] [14]
Pimozide DMW83TP Moderate Increased risk of prolong QT interval by the combination of Formoterol and Pimozide. Schizophrenia [6A20] [14]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Formoterol and LEE011. Solid tumour/cancer [2A00-2F9Z] [22]
Vandetanib DMRICNP Moderate Increased risk of prolong QT interval by the combination of Formoterol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [14]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [14]
Doxorubicin DMVP5YE Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [14]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Pitolisant. Somnolence [MG42] [14]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Formoterol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [14]
Cabozantinib DMIYDT4 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Cabozantinib. Thyroid cancer [2D10] [14]
Fluticasone DMGCSVF Minor Increased risk of hypokalemia by the combination of Formoterol and Fluticasone. Vasomotor/allergic rhinitis [CA08] [12]
Procainamide DMNMXR8 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Procainamide. Ventricular tachyarrhythmia [BC71] [14]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Formoterol and Flecainide. Ventricular tachyarrhythmia [BC71] [14]
Amiodarone DMUTEX3 Moderate Increased risk of prolong QT interval by the combination of Formoterol and Amiodarone. Ventricular tachyarrhythmia [BC71] [14]
⏷ Show the Full List of 104 DDI Information of This Drug

References

1 Formoterol FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3465).
3 Health Canada Product Monograph: Oxeze (formoterol) dry powder inhaler
4 FDA Approved Drug Products: Perforomist? inhalation solution
5 FDA Approved Drug Products: Foradil? Aerolizer inhalation powder
6 Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998 Feb;55(2):303-22.
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
9 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
10 A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
11 FDA Label of Formoterol. The 2020 official website of the U.S. Food and Drug Administration.
12 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
13 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
14 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
15 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
16 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
17 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
18 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
19 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
20 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
21 Cerner Multum, Inc. "Australian Product Information.".
22 Canadian Pharmacists Association.